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The phosphatidykinosital 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin [mTOR] pathway 
is one of the most commonly deregulated pathways in can-
cer.1–3 It is activated by the binding of extracellular growth 
factors to transmembrane receptor tyrosine kinases, including 
epidermal growth factor receptor (EGFR), HER2, insulin-like 
growth factor receptor, vascular endothelial growth factor 
receptor, and platelet-derived growth factor receptor. Among 
the three known classes of phosphatidylinositaol-3-kinases 
(PI3Ks), the most frequently implicated in human cancer are 
class IA phosphatidylinositaol-3-kinases (PI3Ks), which are 
heterodimers of a p110 catalytic subunit and a p85 regulatory 
subunit, which inhibit p110 in the absence of receptor tyrosine 
kinase activation by ligand.2,4,5
PI3K/AKT/mTOR pathway targeting agents are cur-
rently being explored in lung cancer and advanced solid tumors. 
A good understanding of the safety profile of these agents is 
important in consideration of the fact that the PI3K/AKT/
mTOR pathway plays a central role in the regulation of multiple 
cellular processes. To date, rash, hyperglycemia, and transami-
nase elevations seem to be class effects of PI3K/AKT/mTOR 
inhibition. Indeed, because PI3K/AKT/mTOR signaling plays a 
central role in insulin signaling, pathway inhibition can lead to 
insulin resistance.6–8 The agents currently being investigated can 
be broken into multiple categories, depending on their target(s).
SUMMARY OF PRESENTATIONS
PI3K Inhibitors
BKM-120 (Novartis) is an oral highly specific inhibitor of class 
I PI3K. It has shown antiproliferative activity in tumoral cell 
lines and in xenografts bearing PI3K-mutated or PI3K wild-
type tumors.9 However, BKM-120 preferentially inhibits the 
proliferation of tumor cells with PIK3CA gene-bearing onco-
genic mutations.9 It has also shown proapoptotic effects in 
PI3K-mutated breast cancer cell lines.10 In a phase I trial, BKM-
120 was well tolerated and the most frequent grade 3–4 side 
effects, associated with doses of 80 mg or higher, were pruritus, 
mucositis, nausea, fatigue, anorexia, skin rash, hyperglycemia, 
altered mood, and diarrhea.8 Increases in C-peptide were evi-
dent at all doses tested, whereas increases in glucose become 
more evident at doses of 80 mg or higher.8 In the phase I trial, 
16 of 20 patients treated at 80 to 150 mg showed 40% to 85% 
suppression of S6 phosphorylation in skin biopsies at the end of 
cycle 1.8 Several phase I trials are ongoing, testing the associa-
tion of BKM-120 with chemotherapy in solid tumors, including 
colorectal cancer, glioblastoma, and non–small-cell lung cancer 
(NSCLC). In particular, phase I trials in NSCLC are ongoing to 
test BKM-120 in combination with carboplatin and pemetrexed 
in advanced nonsquamous histology and in combination with 
erlotinib in EGFR-mutated lung adenocarcinoma patients pre-
viously sensitive to EGFR tyrosine kinase inhibitors.
The orally bioavailable PI3K inhibitor GDC-0941 
(Genentech) selectively binds to PI3K isoforms p100alpha 
and p100delta (IC50 of 3 nM for both isoforms), and in an 
adenosine triphosphate (ATP)-competitive manner, inhibits 
the production of the secondary messenger phosphatidylino-
sitol-3,4,5-trisphosphate and activation of the PI3K/protein 
kinase B (Akt) signaling pathway. Phase Ib clinical trials for 
metastatic NSCLC are ongoing, evaluating GDC-0941 in 
combination with bevacizumab. A phase II blinded, random-
ized trial is planned, which will test the association of GDC-
0941 with chemotherapy with carboplatin and paclitaxel ± 
bevacizumab depending on histology (squamous or nonsqua-
mous histology) in first-line metastatic NSCLC.
PX-866 is a potent orally available inhibitor of each of the four 
major forms of PI-3 kinase. In testing to date, it does not seem 
to have significant off-target effects. It is broadly active in 
preclinical tumor models, both as a single agent and in com-
binations with other targeted agents, chemotherapeutics and 
radiation.11–14 The most important distinguishing characteris-
tic of PX-866, however, is that it is the only irreversible inhibi-
tor in development, which it achieves by covalently binding to 
the target. This property will facilitate sustained blockade of 
the PI-3 kinase signaling pathway, which may be important in 
achieving clinical benefit and in conferring dose and schedul-
ing advantages, and may potentially result in few off-target 
effects. A phase I trial of single-agent PX-866 in solid tumors 
showed that a continuous schedule of administration had 
similar safety and better disease control than an intermittent 
schedule did. Most common side effects were diarrhea, nau-
sea, vomiting, and reversible alanine aminotransferase (ALT)/
aspartate aminotransferase (AST) elevation.14
A phase I trial of PX-866 in combination with cetux-
imab in patients with metastatic colorectal and head and neck 
cancers showed 50% (4 of 9 patients) partial responses (PR), 
38% (3 of 9 patients) stable disease (SD), and one disease 
progression.15 A phase II trial of PX-866 in combination with 
docetaxel is planned in previously treated metastatic NSCLC 
and head and neck cancer.
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ON-01910 is a potent mitotic inhibitor that targets 
PI3K a and b isoforms. It affects translation of cap-dependent 
mRNAs and reduces level of Cyclin D, C-myc, and other regu-
latory proteins.16 ON-01910 has shown to be well tolerated in 
the phase I trial in combination with gemcitabine in patients 
with advanced tumors with most frequent side effects of neu-
tropenia, thrombocytopenia, and fatigue. It has shown good 
clinical activity in gemcitabine-pretreated pancreatic cancer 
patients and therefore it is currently in phase II trials in meta-
static pancreatic cancer. One NSCLC patient was treated in 
the phase I trial with results of SD at 24 weeks.17
BAY 80–6946 is a potent and highly selective revers-
ible pan-class I PI3K inhibitor with antitumor activity in a 
panel of preclinical models. A phase I dose-escalation mul-
ticenter study in patients with advanced solid tumors showed 
a maximum tolerated dose (MTD) of 0.8 mg/kg.18 The most 
frequent adverse event was hyperglycemia with six of seven 
evaluable patients who received 200 mg/dL or more of insulin 
for glucose, but only within 24 hours of MTD. Other drug-
related adverse events include grade 1/2 fatigue, nausea, vom-
iting, alopecia, diarrhea, mucositis and dysgeusia, and grade 
2/3 anemia. Dose-limiting toxicity (DLT) was seen in one 
patient at 1.2 mg/kg consisting of grade 4 acute left ventric-
ular dysfunction with lactic acidosis, liver dysfunction, and 
renal insufficiency, and grade 4 hyperglycemia, all recover-
ing within several days. At MTD fluorodeoxyglucose (FDG) 
uptake was reduced by 23% in a liver lesion of a pancreatic 
patient and 40% in an NSCLC lesion.18
AKT Inhibitors
MK-2206 (Merck) is a first-in-class allosteric AKT1/2/3 
inhibitor with evidence of preclinical activity and demon-
strates synergistic activity in combination with cytotoxic 
agents (doxorubicin, gemcitabine, docetaxel, and carboplatin) 
in lung NCI-H460 cells. MK-2206 has also been shown to 
enhance erlotinib activity in erlotinib-sensitive and -resistant 
NSCLC cell lines and to resensitize cells rendered resistant 
through c-mesenchymal epithelial transition factor (MET) 
activation by hepatocyte growth factor (HGF).19 In a phase 
I study, single-agent MK-2206 caused tumor regressions in 
a patient with pancreatic cancer with loss of phosphatase 
and tensin homolog (PTEN) expression and caused minor 
tumor regressions in one patient with melanoma and in one 
patient with a neuroendocrine tumor.20 Common reversible 
drug-related toxicities included rash, nausea, fatigue, and 
hyperglycemia. MK-2206 is also undergoing evaluation in 
combination with chemotherapeutic agents and anti-HER2 
therapy in breast cancer patients. In addition, on the basis of 
the preclinical rationale, the combination of MK-2206 and the 
MEK inhibitor AZD6244 (AstraZeneca) has been investigated 
and has shown encouraging activity, notably in NSCLC.21
MK-2206 in combination with MEK inhibition has 
shown more efficacy in a subset of lung cancer cell lines than 
single-agent therapy has.22,23 Phase I combination therapy trial 
has been completed with side effects consisting mainly in 
skin toxicity,20 and phase II trials are underway in metastatic 
NSCLC (the Biomarker-integrated Approaches of Targeted 
Therapy for Lung Cancer Elimination [BATTLE] 2 trial).
Other oral AKT inhibitors in phase I trials in 
cancer patients include GSK2141795, GSK2110183 
(GlaxoSmithKline), GDC-0068 (Genentech), and LY2780301 
(Eli Lilly), which also inhibits p70 S6 kinase. GSK2141795 
was recently reported to demonstrate activity in anal, endo-
metrial, and prostate cancers with reversible hyperglycemia, 
hypoglycemia, and stomatitis being the DLTs.24
mTOR Inhibitors
mTORC1 inhibitors are the most developed class of 
PI3K/AKT/mTOR pathway inhibitors and include evero-
limus, temsirolimus, and ridaforolimus. Everolimus and 
temsirolimus have been approved by the Food and Drug 
Administration for renal cell carcinoma, and everolimus has 
also been approved for subependymal giant cell astrocytoma 
associated with tuberous sclerosis and neuroendocrine tumors 
of pancreatic origin. Ridaforolimus is currently in a phase III 
study of sarcoma.
Everolimus has been studied in multiple clinical trials 
in patients with NSCLC, as single agent or in association with 
pemetrexed or erlotinib.25,26 However, because of the relatively 
modest single-agent activity,27 evidence does not support 
further testing in unselected patient populations. Results of 
phase II trials of everolimus in combination with chemother-
apy or targeted agents have shown limited activity in NSCLC 
patients. In combination with erlotinib, everolimus has shown 
a progression-free survival of 2.9 months and 39% of disease 
control (complete response+ PR +SD).25 The response rate for 
the combination of everolimus and gefitinib was 13% (all PR) 
in patients with advanced NSCLC who had either received no 
prior chemotherapy or had been previously treated with cis-
platin or carboplatin and docetaxel or pemetrexed.28 Similarly, 
only two patients (7%) achieved a PR when everolimus was 
given in combination with docetaxel as a second- or third-line 
treatment.29 The combination of everolimus with pemetrexed 
has shown 12% of responses (PR +complete responses) in 
NSCLC patients who had disease progression after one previ-
ous treatment.26
A phase II trial of ridaforolimus in patients with KRAS-
mutated NSCLC is currently ongoing showing promising 
results. In addition, clinical trials are underway for the com-
bination of retaspimycin + everolimus in KRAS-mutant lung 
cancers and GDC0980 in malignant pleural mesotheliomas.
Limited data of temsirolimus as monotherapy in 
NSCLC have shown minimal efficacy. Selection of patients 
is essential for further clinical trials. A patient with NSCLC 
achieved a PR lasting for 12.7 months in a phase I study in 
patients with advanced solid tumors.30 In a phase II study in 
patients with small-cell lung cancer, temsirolimus was admin-
istered as maintenance therapy after SD or in patients with 
disease that responded to induction therapy with cisplatin or 
carboplatin plus etoposide or irinotecan. In this study, temsi-
rolimus did not seem to increase progression-free survival in 
these patients.31 Clinical trials with other combination part-
ners, such as neratinib and pemetrexed, are ongoing.
Published data from clinical studies with ridaforolimus 
in lung cancer are limited to a single patient achieving a PR 
in a phase I dose-escalation trial in patients with advanced 
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solid tumors.32 Ongoing studies include a phase I combination 
trial with cetuximab in patients with head and neck cancer or 
NSCLC and a phase II trial in NSCLC patients with KRAS 
mutations.
BEZ235 is an orally available inhibitor with high 
selectivity for all three PI3K isoforms.33 It also inhibits sev-
eral other kinases including mTORC1 and mTORC2 kinase 
activity.33 The first phase I clinical trial of BEZ235 in solid 
tumors showed two PRs: one in a patient with lung cancer and 
Cowden syndrome and the other in a heavily pretreated breast 
cancer patient.34 Fourteen patients with different types of solid 
tumors achieved disease stabilization of 4 months or more.34 
Preclinical data on the combination of BEZ235 and RAD-001 
has shown synergy with inhibition of tumor growth,35 and a 
phase I trial testing this combination in solid tumors is cur-
rently in progress.
Development of mTOR kinase inhibitors targeting the 
function of mTORC1 and mTORC2 is ongoing.36 On the 
basis of promising preclinical data, the mTORC1/2 inhibitors 
INK128 (Intellikine), AZD8055 (AstraZeneca), and OSI-027 
(OSI Pharmaceuticals) are entering early clinical trials.37,38 A 
phase I trial with OSI-027 reported disease stabilization in 
eight of 31 treated patients with DLTs of fatigue and decrease 
in left ventricular ejection fraction.38
FUTURE DIRECTIONS
The most recurrent issue in the development of PI3K/
AKT/mTOR pathway inhibitors is the lack of clinical data in 
selected patient populations that carry mutations and/or other 
alterations of the pathway. Therefore, it is difficult to under-
stand the role of these agents in a personalized therapy setting 
in these trials. Prospective screening modalities for pathway 
alterations are being incorporated in more recent trials of PI3K/
AKT/mTOR pathway inhibitors. In fact, the inclusion crite-
ria of the phase I study of BEZ235 (NCT01195376) require 
enrollment of patients with advanced solid tumors harboring 
PIK3CA mutation (or amplification) and/or a PTEN muta-
tion and/or low or null PTEN expression. In studies of rida-
forolimus (NCT00818675) and MK-2206 (NCT01021748), 
patients are required to have KRAS-driven NSCLC. In a study 
sponsored by the National Cancer Institute (NCT01306045), 
patients with lung cancer are prescreened and allocated into 
treatment groups based on the molecular profiles of their 
tumor biopsies. One of the arms of this study is investigating 
MK-2206, which will be used to treat patients with PIK3CA, 
AKT, or PTEN gene mutations. MK-2206 is also being studied 
in a similar study (BATTLE-2; NCT01248247). The results of 
these studies should help to better identify the patients who 
will be best suited for treatment with agents that target the 
PI3K/AKT/mTOR pathway.
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